Ann: Quarterly Appendix 4C and Activities Report, page-71

Nina has mentioned in recent interviews about “lumpy spending” as opening the site has a higher cost but after that operation costs drop if I remember correctly.

Australian R&D tax credits ahead as well as the whopping $460m milestone payments for the two regions that have been negotiated. Positive & negative of the milestones are we don’t know the terms as to what will trigger so as to maintain a stronger negotiating position for new markets but data & reaching 144th patient, successful outcome of trials surely should trigger some $$?




Was surprised by the sudden sell off yesterday and I’ll never understand the markets but glad I didn’t buy ETFs with the funds I put into DXB, it’s an exciting time with negotiations ongoing behind the scenes & 70-80% still on the table for regions revenue potential. Market cap adjustments to happen on next data, milestone payments or new partnerships??

What will be the next pivot or trigger people?